NeuroSense Therapeutics Ltd. (NRSN) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
NeuroSense Therapeutics Ltd. (NRSN) Earnings Overview
As of June 26, 2026, NeuroSense Therapeutics Ltd. (NRSN) reported trailing twelve-month net income of -$9M, reflecting +20.0% year-over-year growth. The company earned $-0.34 per diluted share over the past four quarters.
Looking at the long-term picture, NRSN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$1M in fiscal 2019.
NeuroSense Therapeutics Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRTA (-$151M net income, -2520.6% margin), ACIU (-$70M net income, -1971.6% margin), SAVA (-$106M net income), NRSN has comparable earnings metrics. Compare NRSN vs PRTA →
NRSN Earnings vs Peers
Earnings metrics vs comparable public companies
NRSN Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$11M | -9.0% | -$11M | $-0.44 | - | - |
| 2024 | -$10M | -1.0% | -$10M | $-0.55 | - | - |
| 2023 | -$10M | +18.1% | -$12M | $-0.83 | - | - |
| 2022 | -$12M | -205.4% | -$14M | $-1.07 | - | - |
| 2021 | -$4M | -42.9% | -$6M | $-0.23 | - | - |
| 2020 | -$3M | -130.5% | -$3M | $-0.51 | - | - |
| 2019 | -$1M | - | -$1M | $-0.22 | - | - |
Download Data
Export NRSN earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NRSN — Frequently Asked Questions
Quick answers to the most common questions about buying NRSN stock.
What is NRSN earnings per share (EPS)?
NRSN trailing twelve-month (TTM) diluted EPS is $-0.34, reflecting +20.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is NeuroSense Therapeutics Ltd.'s net income?
NeuroSense Therapeutics Ltd. (NRSN) trailing twelve-month net income is $-9M as of 2025. Earnings grew +20.0% year-over-year.
Is NRSN profitable?
NRSN is not currently profitable on a TTM basis, reporting a net loss of $-9M. Net margin is N/A. Investors should monitor for a return to profitability.
What is NRSN's earnings growth rate?
NRSN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are NRSN's profit margins?
NeuroSense Therapeutics Ltd. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -2175.0%.
Is NRSN growing earnings?
Yes, NRSN earnings are accelerating — EPS growth of +20.0% exceeds the 5-year CAGR of N/A. TTM net income reached $-9M. Earnings momentum is strengthening.
What was NRSN's best earnings year?
NeuroSense Therapeutics Ltd.'s highest annual net income on record is $-1M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were NRSN's earnings last quarter?
NRSN's most recent reported quarter was Q2 2025. Net income was $-2M with diluted EPS of $-0.09. For a full breakdown of all quarters, see the quarterly earnings table on this page.